<p>Cingulate (NASDAQ:CING - 获取免费报告) 预计将在 2026 年 5 月 14 日星期四市场开盘前发布其 2026 年第一季度的财报。分析师预计该公司本季度每股收益为（$0.53）。各方可以在公司即将发布的 2026 年第一季度财报页面找到电话会议的详细信息，最新的电话会议安排在 2026 年 5 月 15 日星期五上午 9:30（东部时间）。</p>
<p>Cingulate (NASDAQ:CING - 获取免费报告) 最近在 3 月 18 日星期三公布了季度财报。该公司报告每股收益（EPS）为（$0.84），低于分析师一致预期的（$0.56），差距为（$0.28）。平均而言，分析师预计 Cingulate 在当前财年将发布每股收益为 $-2，下一财年为 $-1。</p>
<h2>Cingulate 股票上涨 7.0%</h2>
<p>NASDAQ:CING 的股票在星期四以 $5.33 开盘。Cingulate 的一年低点为 $3.20，一年高点为 $11.89。该公司的市值为 6530 万美元，市盈率为 -1.23，贝塔值为 -0.81。公司的债务与股本比率为 0.46，流动比率为 1.16，速动比率为 1.16。该股票的 50 日移动平均线为 $6.46，200 日移动平均线为 $5.24。</p>
<h2>分析师升级与降级</h2>
<p>CING 一直是多份研究分析师报告的主题。Roth Mkm 在 3 月 23 日星期一的报告中将 Cingulate 的目标价从 $16.00 下调至 $14.00，并对该股票给予 “买入” 评级。Weiss Ratings 在 4 月 20 日星期一的报告中重申了对 Cingulate 股票的 “卖出（e+）” 评级。最后，Ascendiant Capital Markets 在 4 月 8 日星期三的报告中将 Cingulate 的目标价从 $58.00 下调至 $55.00，并对该股票给予 “买入” 评级。两位研究分析师对该股票给予了买入评级，一位则给予了卖出评级。根据 MarketBeat.com 的数据，Cingulate 目前的共识评级为 “持有”，平均目标价为 $34.50。</p>
<p><strong>获取我们关于 CING 的最新研究报告</strong></p>
<h2>内部人士买卖</h2>
<p>在其他新闻中，董事彼得·J·沃斯于 2 月 6 日星期五购买了 19,455 股 Cingulate 股票。每股购买价格为 $5.04，总交易额为 $98,053.20。收购后，该董事持有 117,449 股公司股票，估值约为 $591,942.96。这笔交易使他们的持股增加了 19.85%。该收购已在与 SEC 的法律文件中披露，可以通过此链接访问。此外，首席执行官香农·J·沙弗于 2 月 6 日星期五购买了 6,809 股 Cingulate 股票。每股购买价格为 $5.04，总交易额为 $34,317.36。收购后，首席执行官直接持有公司 10,175 股股票，估值约为 $51,282。这笔交易代表了他们持股的 202.29% 增加。该购买的披露信息可在 SEC 文件中找到。内部人士在上个季度共购买了价值 $166,693 的 33,074 股公司股票。公司内部人士持有公司股票的 4.33%。</p>
<h2>机构资金流入与流出</h2>
<p>一些对冲基金和其他机构投资者最近对公司的持仓进行了调整。Kestra Advisory Services LLC 在第四季度将其在 Cingulate 股票中的持仓增加了 29.8%。Kestra Advisory Services LLC 现在拥有 122,000 股公司股票，价值 $529,000，此前在此期间又收购了 27,979 股。Geode Capital Management LLC 在第四季度将其在 Cingulate 股票中的持仓增加了 43.9%。Geode Capital Management LLC 现在拥有 61,035 股公司股票，价值 $265,000，此前在此期间又收购了 18,629 股。DRW Securities LLC 在第四季度购买了 Cingulate 的新头寸，价值约为 $255,000。XTX Topco Ltd 在第四季度购买了 Cingulate 的新头寸，价值约为 $90,000。最后，Quadrature Capital Ltd 在第四季度购买了 Cingulate 的新股份，价值约为 $66,000。对冲基金和其他机构投资者持有公司股票的 41.31%。</p>
<h2>Cingulate 公司简介</h2>
<p>（获取免费报告）</p>
<p>Cingulate Inc 是一家生物制药公司，专注于开发用于治疗美国注意力缺陷/多动障碍和焦虑的药物。该公司的兴奋剂药物包括 CTx-1301（右甲基苯丙胺），目前处于三期临床试验阶段，以及 CTx-1302（右旋安非他命），目前正在进行新药申请开发，旨在治疗儿童、青少年和成人的注意力缺陷/多动障碍。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是 Cingulate</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0lORw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0lORw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 Cingulate 吗？</h2>
<p>在你考虑 Cingulate 之前，你会想听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每天推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买... 而 Cingulate 并不在名单上。</p>
<p>虽然 Cingulate 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

CING

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 3 倍做多 - Direxion

<p>Cingulate (NASDAQ:CING) 将于 5 月 14 日发布 2026 年第一季度财报，分析师预计每股亏损 0.53 美元。该公司此前报告了 2025 年第一季度每股亏损 0.84 美元，未能达到预期。Cingulate 的股票最近上涨了 7%，交易价格为 5.33 美元，市值为 6530 万美元。内部人士的买入活动增加，董事彼得·J·沃斯（Peter J. Werth）和首席执行官香农·J·沙弗（Shane J. Schaffer）进行了大量购买。机构投资者持有该公司 41.31% 的股份，公司专注于注意力缺陷多动障碍（ADHD）和焦虑症的治疗</p>

<p>Cingulate (NASDAQ:CING - Get Free Report) is expected to issue its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect the company to announce earnings of ($0.53) per share for the quarter. Parties can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.</p>
<div class="lb-trans"><p>Cingulate (NASDAQ:CING - 获取免费报告) 预计将在 2026 年 5 月 14 日星期四市场开盘前发布其 2026 年第一季度的财报。分析师预计该公司本季度每股收益为（$0.53）。各方可以在公司即将发布的 2026 年第一季度财报页面找到电话会议的详细信息，最新的电话会议安排在 2026 年 5 月 15 日星期五上午 9:30（东部时间）。</p>
</div><p>Cingulate (NASDAQ:CING - Get Free Report) last announced its quarterly earnings results on Wednesday, March 18th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.28). On average, analysts expect Cingulate to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Cingulate (NASDAQ:CING - 获取免费报告) 最近在 3 月 18 日星期三公布了季度财报。该公司报告每股收益（EPS）为（$0.84），低于分析师一致预期的（$0.56），差距为（$0.28）。平均而言，分析师预计 Cingulate 在当前财年将发布每股收益为 $-2，下一财年为 $-1。</p>
</div><h2>Cingulate Stock Up 7.0%</h2>
<div class="lb-trans"><h2>Cingulate 股票上涨 7.0%</h2>
</div><p>Shares of NASDAQ:CING opened at $5.33 on Thursday. Cingulate has a 1 year low of $3.20 and a 1 year high of $11.89. The company has a market cap of $65.30 million, a PE ratio of -1.23 and a beta of -0.81. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.16 and a quick ratio of 1.16. The stock's 50-day moving average is $6.46 and its 200 day moving average is $5.24.</p>
<div class="lb-trans"><p>NASDAQ:CING 的股票在星期四以 $5.33 开盘。Cingulate 的一年低点为 $3.20，一年高点为 $11.89。该公司的市值为 6530 万美元，市盈率为 -1.23，贝塔值为 -0.81。公司的债务与股本比率为 0.46，流动比率为 1.16，速动比率为 1.16。该股票的 50 日移动平均线为 $6.46，200 日移动平均线为 $5.24。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级与降级</h2>
</div><p>CING has been the topic of a number of research analyst reports. Roth Mkm reduced their price target on Cingulate from $16.00 to $14.00 and set a &#34;buy&#34; rating on the stock in a report on Monday, March 23rd. Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of Cingulate in a report on Monday, April 20th. Finally, Ascendiant Capital Markets reduced their price target on Cingulate from $58.00 to $55.00 and set a &#34;buy&#34; rating on the stock in a report on Wednesday, April 8th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Cingulate currently has a consensus rating of &#34;Hold&#34; and an average price target of $34.50.</p>
<div class="lb-trans"><p>CING 一直是多份研究分析师报告的主题。Roth Mkm 在 3 月 23 日星期一的报告中将 Cingulate 的目标价从 $16.00 下调至 $14.00，并对该股票给予 “买入” 评级。Weiss Ratings 在 4 月 20 日星期一的报告中重申了对 Cingulate 股票的 “卖出（e+）” 评级。最后，Ascendiant Capital Markets 在 4 月 8 日星期三的报告中将 Cingulate 的目标价从 $58.00 下调至 $55.00，并对该股票给予 “买入” 评级。两位研究分析师对该股票给予了买入评级，一位则给予了卖出评级。根据 MarketBeat.com 的数据，Cingulate 目前的共识评级为 “持有”，平均目标价为 $34.50。</p>
</div><p><strong>Get Our Latest Research Report on CING</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 CING 的最新研究报告</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人士买卖</h2>
</div><p>In other news, Director Peter J. Werth bought 19,455 shares of Cingulate stock in a transaction on Friday, February 6th. The shares were purchased at an average price of $5.04 per share, for a total transaction of $98,053.20. Following the acquisition, the director owned 117,449 shares of the company's stock, valued at approximately $591,942.96. The trade was a 19.85% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Shane J. Schaffer bought 6,809 shares of Cingulate stock in a transaction on Friday, February 6th. The shares were purchased at an average price of $5.04 per share, for a total transaction of $34,317.36. Following the acquisition, the chief executive officer directly owned 10,175 shares in the company, valued at approximately $51,282. This trade represents a 202.29% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 33,074 shares of company stock worth $166,693 in the last quarter. Company insiders own 4.33% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，董事彼得·J·沃斯于 2 月 6 日星期五购买了 19,455 股 Cingulate 股票。每股购买价格为 $5.04，总交易额为 $98,053.20。收购后，该董事持有 117,449 股公司股票，估值约为 $591,942.96。这笔交易使他们的持股增加了 19.85%。该收购已在与 SEC 的法律文件中披露，可以通过此链接访问。此外，首席执行官香农·J·沙弗于 2 月 6 日星期五购买了 6,809 股 Cingulate 股票。每股购买价格为 $5.04，总交易额为 $34,317.36。收购后，首席执行官直接持有公司 10,175 股股票，估值约为 $51,282。这笔交易代表了他们持股的 202.29% 增加。该购买的披露信息可在 SEC 文件中找到。内部人士在上个季度共购买了价值 $166,693 的 33,074 股公司股票。公司内部人士持有公司股票的 4.33%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入与流出</h2>
</div><p>A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Kestra Advisory Services LLC grew its holdings in shares of Cingulate by 29.8% during the 4th quarter. Kestra Advisory Services LLC now owns 122,000 shares of the company's stock worth $529,000 after acquiring an additional 27,979 shares during the period. Geode Capital Management LLC grew its holdings in shares of Cingulate by 43.9% during the 4th quarter. Geode Capital Management LLC now owns 61,035 shares of the company's stock worth $265,000 after acquiring an additional 18,629 shares during the period. DRW Securities LLC purchased a new position in shares of Cingulate during the 4th quarter worth approximately $255,000. XTX Topco Ltd purchased a new position in shares of Cingulate during the 4th quarter worth approximately $90,000. Finally, Quadrature Capital Ltd purchased a new stake in shares of Cingulate in the 4th quarter worth approximately $66,000. Hedge funds and other institutional investors own 41.31% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近对公司的持仓进行了调整。Kestra Advisory Services LLC 在第四季度将其在 Cingulate 股票中的持仓增加了 29.8%。Kestra Advisory Services LLC 现在拥有 122,000 股公司股票，价值 $529,000，此前在此期间又收购了 27,979 股。Geode Capital Management LLC 在第四季度将其在 Cingulate 股票中的持仓增加了 43.9%。Geode Capital Management LLC 现在拥有 61,035 股公司股票，价值 $265,000，此前在此期间又收购了 18,629 股。DRW Securities LLC 在第四季度购买了 Cingulate 的新头寸，价值约为 $255,000。XTX Topco Ltd 在第四季度购买了 Cingulate 的新头寸，价值约为 $90,000。最后，Quadrature Capital Ltd 在第四季度购买了 Cingulate 的新股份，价值约为 $66,000。对冲基金和其他机构投资者持有公司股票的 41.31%。</p>
</div><h2>Cingulate Company Profile</h2>
<div class="lb-trans"><h2>Cingulate 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.</p>
<div class="lb-trans"><p>Cingulate Inc 是一家生物制药公司，专注于开发用于治疗美国注意力缺陷/多动障碍和焦虑的药物。该公司的兴奋剂药物包括 CTx-1301（右甲基苯丙胺），目前处于三期临床试验阶段，以及 CTx-1302（右旋安非他命），目前正在进行新药申请开发，旨在治疗儿童、青少年和成人的注意力缺陷/多动障碍。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Cingulate</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Cingulate</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0lORw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=CING"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cingulate Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Cingulate 吗？</h2>
</div><p>Before you consider Cingulate, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Cingulate 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cingulate wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每天推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买... 而 Cingulate 并不在名单上。</p>
</div><p>While Cingulate currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Cingulate 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Cingulate (CING) 将在周四公布季度财报